Stock listing
Shanghai:688315 Novogene Co., Ltd. (诺禾致源) 股价
Follow Novogene Co., Ltd. into a list and get an email when it puts out news.
Share price · SSE:688315
¥15.20 CNY -1.76 (-10.4%)
Close on Nov 20, 2026
- Day range
- ¥15.08 – ¥15.77 CNYNov 20, 2026
- Volume
- 10.42M sharesNov 20, 2026
- Market cap
- ¥6.33B CNYAt the close on Nov 20, 2026 · price × 416.2M shares outstanding
- 52-week range
- ¥11.46 – ¥23.43 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥354.2M CNYMedian day 19.15M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688315 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥15.20 | -1.76 | -10.4% | ¥15.68 | ¥15.77 | ¥15.08 | 10,423,267 | |
| ¥16.96 | -0.40 | -2.3% | ¥17.64 | ¥17.64 | ¥16.47 | 14,038,607 | |
| ¥17.36 | -0.65 | -3.6% | ¥17.74 | ¥18.20 | ¥17.20 | 13,260,621 | |
| ¥18.01 | +0.13 | +0.7% | ¥17.52 | ¥18.98 | ¥16.74 | 20,672,782 | |
| ¥17.88 | -1.73 | -8.8% | ¥19.56 | ¥19.86 | ¥17.81 | 19,112,784 | |
| ¥19.61 | -0.71 | -3.5% | ¥20.10 | ¥20.88 | ¥19.61 | 17,414,857 | |
| ¥20.32 | +0.46 | +2.3% | ¥20.17 | ¥20.39 | ¥19.38 | 16,253,712 | |
| ¥19.86 | +0.74 | +3.9% | ¥19.70 | ¥20.20 | ¥19.16 | 19,563,202 | |
| ¥19.12 | +0.54 | +2.9% | ¥18.70 | ¥20.15 | ¥18.63 | 16,161,780 | |
| ¥18.58 | -0.67 | -3.5% | ¥18.46 | ¥19.48 | ¥18.16 | 19,178,239 | |
| ¥19.25 | +2.00 | +11.6% | ¥17.14 | ¥19.44 | ¥17.03 | 29,664,195 | |
| ¥17.25 | +0.79 | +4.8% | ¥16.33 | ¥17.40 | ¥15.38 | 28,150,238 | |
| ¥16.46 | -2.37 | -12.6% | ¥18.70 | ¥18.70 | ¥16.45 | 25,077,851 | |
| ¥18.83 | +0.52 | +2.8% | ¥18.33 | ¥19.12 | ¥17.32 | 21,484,648 | |
| ¥18.31 | -0.94 | -4.9% | ¥18.98 | ¥20.35 | ¥17.51 | 29,352,442 | |
| ¥19.25 | -0.64 | -3.2% | ¥19.69 | ¥20.60 | ¥19.21 | 26,447,938 | |
| ¥19.89 | +3.05 | +18.1% | ¥16.84 | ¥20.21 | ¥16.84 | 32,672,232 | |
| ¥16.84 | -1.21 | -6.7% | ¥18.14 | ¥18.23 | ¥16.78 | 14,630,920 | |
| ¥18.05 | -1.30 | -6.7% | ¥19.01 | ¥19.10 | ¥17.55 | 21,043,763 | |
| ¥19.35 | +1.16 | +6.4% | ¥17.78 | ¥19.47 | ¥16.90 | 22,445,235 | |
| ¥18.19 | -1.45 | -7.4% | ¥19.89 | ¥19.92 | ¥18.14 | 23,224,304 | |
| ¥19.64 | +1.41 | +7.7% | ¥19.30 | ¥21.19 | ¥18.91 | 33,300,172 | |
| ¥18.23 | +0.91 | +5.3% | ¥17.08 | ¥18.66 | ¥16.70 | 19,030,713 | |
| ¥17.32 | -0.51 | -2.9% | ¥17.48 | ¥18.45 | ¥16.54 | 22,374,737 | |
| ¥17.83 | -1.33 | -6.9% | ¥19.00 | ¥20.77 | ¥17.48 | 27,112,243 | |
| ¥19.16 | -0.47 | -2.4% | ¥18.20 | ¥21.10 | ¥18.20 | 23,094,888 | |
| ¥19.63 | -0.92 | -4.5% | ¥20.14 | ¥20.59 | ¥19.56 | 18,083,443 | |
| ¥20.55 | -1.46 | -6.6% | ¥21.13 | ¥21.60 | ¥19.95 | 27,407,211 | |
| ¥22.01 | +0.28 | +1.3% | ¥21.60 | ¥23.43 | ¥20.78 | 39,417,070 | |
| ¥21.73 | +2.80 | +14.8% | ¥18.91 | ¥22.55 | ¥17.41 | 37,935,026 | |
| ¥18.93 | -0.84 | -4.2% | ¥20.14 | ¥20.47 | ¥18.59 | 27,194,790 | |
| ¥19.77 | +0.87 | +4.6% | ¥18.69 | ¥21.17 | ¥18.57 | 30,215,584 | |
| ¥18.90 | -1.16 | -5.8% | ¥19.84 | ¥20.05 | ¥18.61 | 27,245,141 | |
| ¥20.06 | -0.34 | -1.7% | ¥20.99 | ¥21.40 | ¥19.39 | 29,138,815 | |
| ¥20.40 | +1.01 | +5.2% | ¥19.23 | ¥21.49 | ¥18.70 | 35,993,118 | |
| ¥19.39 | +0.37 | +1.9% | ¥18.98 | ¥19.67 | ¥18.41 | 27,589,940 | |
| ¥19.02 | +0.84 | +4.6% | ¥19.33 | ¥20.18 | ¥18.44 | 49,413,691 | |
| ¥18.18 | +3.03 | +20.0% | ¥16.59 | ¥18.18 | ¥16.42 | 17,898,053 | |
| ¥15.15 | +1.18 | +8.4% | ¥14.14 | ¥16.04 | ¥14.13 | 16,615,933 | |
| ¥13.97 | +0.21 | +1.5% | ¥13.69 | ¥14.48 | ¥13.50 | 7,696,904 | |
| ¥13.76 | +0.47 | +3.5% | ¥13.35 | ¥13.87 | ¥13.18 | 4,404,522 | |
| ¥13.29 | -0.28 | -2.1% | ¥13.39 | ¥13.66 | ¥13.28 | 3,569,180 | |
| ¥13.57 | +0.76 | +5.9% | ¥12.81 | ¥13.61 | ¥12.70 | 6,532,575 | |
| ¥12.81 | -0.54 | -4.0% | ¥13.29 | ¥13.29 | ¥12.69 | 4,899,243 | |
| ¥13.35 | -0.47 | -3.4% | ¥13.77 | ¥13.78 | ¥13.30 | 4,616,195 | |
| ¥13.82 | -0.19 | -1.4% | ¥13.88 | ¥13.94 | ¥13.68 | 4,325,839 | |
| ¥14.01 | +0.21 | +1.5% | ¥13.80 | ¥14.10 | ¥13.56 | 5,220,406 | |
| ¥13.80 | -0.15 | -1.1% | ¥13.95 | ¥14.00 | ¥13.67 | 4,512,092 | |
| ¥13.95 | -0.18 | -1.3% | ¥14.29 | ¥14.45 | ¥13.89 | 5,630,873 | |
| ¥14.13 | -0.21 | -1.5% | ¥14.20 | ¥14.56 | ¥14.07 | 4,608,277 | |
| ¥14.34 | -0.34 | -2.3% | ¥14.73 | ¥14.74 | ¥14.25 | 5,454,783 | |
| ¥14.68 | -0.10 | -0.7% | ¥14.78 | ¥14.98 | ¥14.56 | 5,818,040 | |
| ¥14.78 | -0.75 | -4.8% | ¥15.18 | ¥15.26 | ¥14.67 | 7,172,150 | |
| ¥15.53 | -0.51 | -3.2% | ¥15.81 | ¥16.13 | ¥15.39 | 9,281,856 | |
| ¥16.04 | +0.22 | +1.4% | ¥15.70 | ¥16.73 | ¥15.41 | 12,822,554 | |
| ¥15.82 | -0.25 | -1.6% | ¥16.50 | ¥16.50 | ¥15.65 | 11,625,147 | |
| ¥16.07 | -0.86 | -5.1% | ¥17.01 | ¥17.01 | ¥15.76 | 17,487,541 | |
| ¥16.93 | +0.98 | +6.1% | ¥15.95 | ¥17.09 | ¥15.51 | 22,325,603 | |
| ¥15.95 | -1.15 | -6.7% | ¥16.47 | ¥17.49 | ¥15.75 | 30,386,001 | |
| ¥17.10 | +2.23 | +15.0% | ¥16.40 | ¥17.84 | ¥16.20 | 29,004,320 |
- Ticker
- Shanghai:688315
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Shanghai
- Currency
- CNY
What changed lately
Latest news release · Nov 6, 2026
(688315)"NOVOGENE CO., LTD."Voluntary Announcement
Latest news
(688315)"NOVOGENE CO., LTD."Voluntary Announcement
Nov 6, 2026
Closed ¥18.58 (-3.5%) on Nov 6, 2026
(688315)"NOVOGENE CO., LTD."Report for Q3 2026
Oct 29, 2026
Closed ¥19.25 (-3.2%) on Oct 29, 2026
(688315)"NOVOGENE CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
Oct 29, 2026
Closed ¥19.25 (-3.2%) on Oct 29, 2026
Announcement on Abnormal Fluctuations in Stock Trading
Sep 23, 2026
Closed ¥19.39 (+1.9%) on Sep 23, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
Sep 11, 2026
Closed ¥12.81 (-4.0%) on Sep 11, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
Aug 26, 2026
Closed ¥15.82 (-1.6%) on Aug 26, 2026
Voluntary Announcement
Jun 10, 2026
Closed ¥12.77 (-1.4%) on Jun 10, 2026
Announcement on Implementation of Dividend Distribution for 2025
Jun 3, 2026
Closed ¥13.79 (-2.1%) on Jun 3, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 9, 2026
Closed ¥16.00 (+5.8%) on May 11, 2026
Announcement on Revising and Formulating Some Corporate Governance Systems
Apr 15, 2026
Closed ¥14.53 (-1.0%) on Apr 15, 2026
Novogene Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 11 in the last 12 months · 43 in all · newest Nov 6, 2026 · oldest 2024
Valuation
P/E 43.1× against a median of 18.8×: 5th lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥4.57B CNY
- P/E
- 43.1×
- EV/sales
- 2.0×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.3×
- Gross margin
- 43.1%
- Operating margin
- 6.9%
- Net margin
- 6.4%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Novogene Co., Ltd. Class A · SSE:688315 | US$949.6M | US$685.6M | 43.1× | 2.0× | n/a | 2.3× | 6.4% | 0.0× | n/a |
| Beijing Strong Biotechnologies Inc Class A · SZSE:300406 | US$1.05B | US$1.13B | 28.0× | 5.5× | n/a | 1.9× | 18.2% | 0.3× | n/a |
| Freenome, Inc. · NASDAQ:FRNM | US$1.04B | US$863.3M | 9.5× | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Maravai LifeSciences Holdings, Inc. · NASDAQ:MRVI | US$1.04B | US$1.11B | n/a | 5.2× | n/a | 5.3× | −30.8% | 0.8× | 1.56 |
| Suzhou Novoprotein Scientific Co., Ltd. Class A · SSE:688137 | US$1.02B | US$909.1M | n/a | 38.0× | n/a | 3.4× | −60.8% | 0.0× | n/a |
| Castle Biosciences, Inc. · NASDAQ:CSTL | US$1.01B | US$745.1M | n/a | 2.0× | n/a | 2.1× | −6.1% | 0.0× | 1.00 |
| Guangzhou Wondfo Biotech Co., Ltd. Class A · SZSE:300482 | US$1.01B | US$785.0M | n/a | 2.7× | n/a | 1.2× | −3.2% | 0.0× | n/a |
| St Pharm Co., Ltd. · KRX:237690 | US$992.8M | US$866.1M | 17.4× | 3.0× | 11.1× | 2.1× | 19.9% | 0.0× | n/a |
| Daan Gene Co., Ltd. Class A · SZSE:002030 | US$990.1M | US$810.9M | n/a | 7.0× | n/a | 0.9× | −95.7% | 0.0× | n/a |
| Amoy Diagnostics Co., Ltd. Class A · SZSE:300685 | US$967.3M | US$801.3M | 18.8× | 4.4× | n/a | 3.3× | 28.5% | 0.1× | n/a |
| Innovita Biological Technology Co., Ltd. Class A · SSE:688253 | US$925.5M | US$658.4M | 113× | 14.2× | n/a | 3.0× | 17.7% | 0.0× | n/a |
| Median of the others | US$1.01B | US$837.1M | 18.8× | 5.2× | 11.1× | 2.1× | −3.2% | 0.0× | 1.28 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.53 CNY · Analysts' mean
- EPS, year to Dec 2026
- 0.52 · 1 analyst
- Revenue, year to Dec 2026
- 2.4B · 3 analysts
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 31, 2023 · Before open | +0.4% |
| Q1 2023 | Apr 12, 2023 · Before open | +4.2% |
| Q3 2022 | Oct 24, 2022 · Before open | −2.3% |
| Q2 2022 | Aug 10, 2022 · After close | +7.5% |
| Q1 2022 | Apr 26, 2022 · Before open | −3.7% |
| Q4 2021 | Feb 24, 2022 · After close | +9.4% |
| Quarter to Sep 30, 2021 | Oct 25, 2021 · Before open | +4.7% |
| Quarter to Jun 30, 2021 | Aug 13, 2021 · After close | −11.0% |
| Quarter to Mar 31, 2021 | Apr 27, 2021 · Before open | +20.0% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 2.11B | 2.00B | 1.93B | 1.87B | 1.49B | 1.53B | 1.05B | 739.3M | 458.5M |
| Cost of revenue | 1.27B | 1.19B | 1.15B | 1.08B | 1.07B | 972.4M | 934.0M | 601.7M | 422.9M | 238.4M |
| Gross profit | 939.8M | 917.6M | 852.4M | 849.1M | 793.9M | 517.6M | 600.8M | 451.8M | 316.5M | 220.1M |
| Research and development | 159.9M | 131.7M | 124.2M | 125.6M | 145.3M | 112.3M | 125.7M | 79.4M | 50.4M | 30.5M |
| Selling, general and administrative | 175.3M | 156.1M | 176.1M | 171.0M | 148.1M | 121.7M | 116.8M | 94.1M | 73.0M | 45.1M |
| Operating income | 193.5M | 234.0M | 214.9M | 212.5M | 246.5M | 36.1M | 119.3M | 112.9M | 88.9M | 44.3M |
| Depreciation and amortization | 149.1M | 159.2M | 152.5M | 132.1M | 131.0M | 105.7M | 88.8M | 81.9M | 48.0M | 21.3M |
| EBITDA | 342.6M | 393.1M | 367.3M | 344.5M | 377.5M | 141.7M | 208.1M | 194.8M | 136.9M | 65.6M |
| Interest expense | 1.84M | 2.92M | 3.54M | 3.91M | 4.47M | 11.9M | 3.64M | 1.02M | 2.63M | 1.11M |
| Income before tax | 192.9M | 224.7M | 212.6M | 208.6M | 246.5M | 35.5M | 119.2M | 112.9M | 88.9M | 49.6M |
| Income tax | 20.9M | 29.4M | 27.0M | 17.6M | 1.09M | 4.78M | 15.0M | 7.81M | 10.5M | |
| Net income | 166.1M | 196.8M | 178.1M | 177.2M | 225.2M | 36.5M | 114.3M | 97.1M | 80.5M | 39.1M |
| Earnings per share, basic | 0.41 | 0.48 | 0.44 | 0.44 | 0.58 | 0.10 | 0.32 | 0.27 | 0.22 | 0.34 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 481.5M | 387.4M | 704.7M | 851.3M | 897.8M | 460.0M | 316.1M | 188.6M | 158.4M | 253.0M |
| Short-term investments | 1.29B | 1.25B | 826.9M | 191.1M | 166.2M | 30.0M | 52.0M | |||
| Receivables | 600.0M | 610.5M | 576.2M | 615.6M | 537.2M | 322.4M | 380.1M | 190.9M | 100.9M | 49.1M |
| Inventory | 294.7M | 163.7M | 181.5M | 197.1M | 230.6M | 201.6M | 197.8M | 146.1M | 140.8M | 87.5M |
| Current assets | 2.92B | 2.54B | 2.52B | 2.02B | 1.91B | 1.20B | 1.12B | 681.1M | 704.6M | 1.02B |
| Total assets | 3.94B | 3.64B | 3.59B | 3.05B | 2.86B | 2.02B | 1.97B | 1.47B | 1.35B | 1.23B |
| Accounts payable | 250.7M | 179.0M | 159.0M | 131.7M | 238.7M | 158.1M | 194.4M | 58.4M | 29.4M | 21.4M |
| Current liabilities | 1.21B | 1.10B | 1.09B | 1.03B | 1.02B | 897.5M | 872.9M | 487.0M | 472.6M | 416.5M |
| Total debt | 13.8M | 17.8M | 49.3M | 44.8M | 71.3M | 182.4M | 52.1M | 94.9M | ||
| Total liabilities | 1.26B | 1.12B | 1.12B | 1.07B | 1.06B | 903.9M | 883.2M | 499.2M | 487.9M | 433.6M |
| Shareholders' equity | 2.65B | 2.49B | 2.46B | 1.96B | 1.79B | 1.12B | 1.08B | 967.7M | 863.1M | 792.5M |
| Shares outstanding | 405.2M | 410.0M | 404.7M | 402.8M | 386.8M | 365.4M | 357.1M | 359.6M | 365.9M | 115.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 217.0M | 385.5M | 334.2M | 303.9M | 293.5M | 342.1M | 85.4M | 151.4M | 54.8M | 95.4M |
| Capital spending | -104.2M | -182.6M | -116.7M | -217.2M | -112.0M | -92.1M | -172.6M | -81.1M | -496.9M | -127.8M |
| Free cash flow | 112.7M | 203.0M | 217.5M | 86.7M | 181.5M | 250.0M | -87.2M | 70.3M | -442.2M | -32.4M |
| Cash from investing | -514.0M | -784.6M | -349.1M | -191.8M | -73.9M | -139.6M | -19.4M | -106.0M | -507.2M | |
| Cash from financing | -179.8M | 289.7M | -44.8M | 358.8M | -119.2M | 179.7M | -51.4M | -315.5K | 503.4M | |
| Dividends paid | -20.3M | -19.4M | -19.5M | -24.3M | -2.48M | -9.27M | -2.33M | -557.2K | -1.85M | -3.37M |
| Share buybacks | -144.2M | |||||||||
| Change in cash | 93.8M | -309.9M | -135.1M | -64.2M | 442.8M | 134.3M | 126.8M | 89.4M | -55.3M | 92.5M |
Filings
All 42 filings
Cap table
Built by 6ix from Novogene Co., Ltd. Class A’s releases
- Common shares
- 416,200,000
- Fully diluted
- 416,200,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 416,200,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 416,200,000 |
Log in to ask 6ix AI your own questions about Novogene Co., Ltd.